St. Jude Medical Inc. 's recent announcement that it will acquire Endocardial Solutions Inc. (ESI) represents the latest step in St. Jude's aggressive strategy to become a dominant player in the atrial fibrillation (AF) market. [See Deal] Buying ESI is St. Jude's third deal in this space in the past four months, preceded by its purchase of Irvine Biomedical Inc. and the completion of its acquisition of Epicor Medical Inc. [See Deal][See Deal]
Establishing itself as a leader in the AF market is an important part of St. Jude's long-term growth strategy, particularly...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?